Literature DB >> 29872481

Primary Hyperparathyroidism Focused on Molecular Pathogenesis.

José Manuel Gómez Sáez1.   

Abstract

Primary hyperparathyroidism (PHPT) is a common cause of hypercalcaemia. The most common lesion found in patients is the solitary benign parathyroid adenoma. Multiple parathyroid adenomas have also been reported. Parathyroid carcinomas are an uncommon cause of PHPT. In 15% of patients, all four parathyroid glands are involved and it may be associated with a familial hereditary syndrome, such as multiple endocrine neoplasia, types 1, 2A and 4. PHPT jaw tumour syndrome is associated with fibromas in the mandible and tumours can also be present in the kidneys and the uterus. No predisposing germline DNA variants in parathyroid adenomas have been demonstrated and only a few clonally altered genes that drive parathyroid tumorigenesis have been identified. Frequently parathyroid adenomas have HRPT2 gene mutations that are likely to be of pathogenetic importance. Mutations in the MEN1 gene (localised to 11q13) are responsible for multiple endocrine neoplasia 1. Multiple endocrine neoplasia 2A, which can be associated with medullary thyroid cancer, is due to a germline mutation of the RET proto-oncogene located on chromosome 10. In MEN1-like negative patients some of the germline mutations in this new susceptibility gene were due to gene CDKN1B (12p13). This new syndrome was classified as multiple endocrine neoplasia 4. In PHPT jaw tumour syndrome, HRPT2, the gene on the long arm of chromosome 1, is responsible for the syndrome. It is suggested to perform genetic testing in patients with PHPT below the age of 30 years, but at any age in patients presenting with multigland parathyroid disease.

Entities:  

Keywords:  Hypercalcaemia; multiple endocrine neoplasia; parathyroidectomy; pathogenesis; primary hyperparathyroidism; primary hyperparathyroidism jaw tumour syndrome

Year:  2014        PMID: 29872481      PMCID: PMC5983086          DOI: 10.17925/EE.2014.10.02.153

Source DB:  PubMed          Journal:  Eur Endocrinol        ISSN: 1758-3772


  34 in total

Review 1.  Renal impairment as a surgical indication in primary hyperparathyroidism: do the data support this recommendation?

Authors:  Chase D Hendrickson; Daniel J Castro Pereira; Richard J Comi
Journal:  J Clin Endocrinol Metab       Date:  2014-04-23       Impact factor: 5.958

2.  Multiple parathyroid adenomas: report of thirty-three cases.

Authors:  J N Attie; G Bock; L J Auguste
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

Review 3.  p27kip1: a new multiple endocrine neoplasia gene?

Authors:  Ilaria Marinoni; Natalia S Pellegata
Journal:  Neuroendocrinology       Date:  2010-10-27       Impact factor: 4.914

4.  Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women.

Authors:  E Lundgren; J Rastad; E Thrufjell; G Akerström; S Ljunghall
Journal:  Surgery       Date:  1997-03       Impact factor: 3.982

5.  The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations.

Authors:  Atsushi Ozawa; Sunita K Agarwal; Carmen M Mateo; A Lee Burns; Terri S Rice; Patricia A Kennedy; Caitlin M Quigley; William F Simonds; Lee S Weinstein; Settara C Chandrasekharappa; Francis S Collins; Allen M Spiegel; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2007-02-13       Impact factor: 5.958

6.  The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene.

Authors:  Ling Lin; Jian-Hua Zhang; Leelamma M Panicker; William F Simonds
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

7.  Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.

Authors:  Julien Thevenon; Abderrahmane Bourredjem; Laurence Faivre; Catherine Cardot-Bauters; Alain Calender; Arnaud Murat; Sophie Giraud; Patricia Niccoli; Marie-Françoise Odou; Françoise Borson-Chazot; Anne Barlier; Catherine Lombard-Bohas; Eric Clauser; Antoine Tabarin; Béatrice Parfait; Olivier Chabre; Emilie Castermans; Albert Beckers; Philippe Ruszniewski; Morgane Le Bras; Brigitte Delemer; Philippe Bouchard; Isabelle Guilhem; Vincent Rohmer; Bernard Goichot; Philippe Caron; Eric Baudin; Philippe Chanson; Lionel Groussin; Hélène Du Boullay; Georges Weryha; Pierre Lecomte; Alfred Penfornis; Hélène Bihan; Françoise Archambeaud; Véronique Kerlan; Françoise Duron; Jean-Marc Kuhn; Bruno Vergès; Michel Rodier; Michel Renard; Jean-Louis Sadoul; Christine Binquet; Pierre Goudet
Journal:  Hum Mol Genet       Date:  2013-01-31       Impact factor: 6.150

8.  Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Authors:  Peter P Truran; Sarah J Johnson; Richard D Bliss; Thomas W J Lennard; Sebastian R Aspinall
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

Review 9.  Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene.

Authors:  Manuel C Lemos; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2008-01       Impact factor: 4.878

Review 10.  Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation.

Authors:  Cornelis J Lips; Koen M Dreijerink; Jo W Höppener
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

View more
  1 in total

1.  Association of Famine Exposure on the Changing Clinical Phenotypes of Primary Hyperparathyroidism in 20 years.

Authors:  Tian-Jiao Yuan; Yu-Ying Yang; Min-Ting Zhu; Yang He; Lin Zhao; Wen-Zhong Zhou; Ting-Wei Su; Hong-Yan Zhao; Li-Hao Sun; Bei Tao; Jian-Min Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.